CCRCC patients with high PANX2 RNA levels had a 2.571-fold (95% CI; 1.902–3.475, P < 0.001) greater risk of death compared to CCRCC patients with low expression of PANX2 RNA. This evidence concerns the gene PANX2 and nonpapillary renal cell carcinoma.